Cancer Research
RECNAC ,
Fatty Acid ,
Lipoic-Acid ,
Natural Extracts ,
Bindweed ,
LF Bacterium
The RECNAC project was started in 1989 with the stated goal, contingent upon attaining set funding goals, to discover why cancer develops in humans and to devise methods for treating and preventing it without damaging normal tissue. All this within a ten year period! At the time it seemed absurd for a small institute such as ours to set such lofty goals when decades of cancer research, by thousands of brilliant scientists, at a host of prestigious institutions spending billions of dollars, had failed to find the elusive cure.
| Video: (00:48) |
Brief Introduction to the RECNAC project by Hugh Riordan, M.D. |
However, we had reasons to aim high. First, by setting our sights on the ultimate goal of a cure, we would be less likely to fall into the common practice of settling for lesser goals (to be published, to be respected in our profession, to earn NIH research grants, to achieve tenure, etc.) that might limit our progress. Second, by setting a finite time period for doing research, we would have an incentive to concentrate on areas that would lead to clinical applications. Finally, because of the Center’s nutrition based approach to medicine, the RECNAC project would be concentrating its research on areas that have been neglected by mainstream science.
The funding goals were not achieved, though the project was generously supported. However, we were able to undertake a variety of ambitious projects, and were extremely productive for an institute of our size. Eleven years after the start of the RECNAC project, we are proud to state our accomplishments: achievements that we feel offer new options and hope to cancer patients.
Ten Major RECNAC Accomplishments Relevant to Cancer Patients
1. Through the publication of papers, lectures, sponsorship of seminars and conferences and the establishment of interactive websites, we seek to spread knowledge of how cancers grow, alternative treatment possibilities and the importance of measurable, optimal nutrition for the prevention of cancer.
In the coming months, information derived from RECNAC research will be internet accessible at www.brightspot.org/recnac/. This report will be available on that website tomorrow afternoon.
| Video: (12:26) |
Discussion on Cancer Prevention by James Jackson, Ph.D.
|
2. Demonstrated that vitamin C is toxic to tumor cells at concentrations that are achievable with high dose intravenous infusions.
3. Further demonstrated that when vitamin C is combined with lipoic acid, the dose required for tumor-cell killing decreases.
4. Demonstrated that vitamin C can be administered intravenously at sustained doses of at least 50g/day for 8 weeks without causing renal complications or significant alterations in blood counts or chemistry profiles.
5. Obtained evidence that vitamin C supplementation improves some parameters of immune cell functioning.
6. Successfully improved the condition of several cancer patients through the use of intravenous vitamin C, or combination of intravenous vitamin C with other antioxidants and immune stimulating agents.
| Video: (14:48) |
Overview of Vitamin C Therapy by Joseph Casciari, Ph.D.
|
7. Developed and tested a non-toxic extract from a locally grown plant that is capable of halting new blood vessel growth and inhibiting tumor growth.
8. Developed a method for producing an immune stimulant from bacterial culture that exhibits significant anti-tumor activity.
| Video: (10:52) |
Review of natural, non-toxic, anti cancer agents by Xiaolong Meng, M.D.
|
9. Developed a method by which a patient’s white blood cells can be used to produce an autologous cytokine cocktail, and developed a protocol for administering this cocktail as a biological response modifier for cancer patients.
10. Gained the ability to grow dendritic cells and train them with tumor antigens obtained from the patient or produced cheaply in the laboratory. These antigen trained dendritic cells can be infused into patients to boost tumor-specific immune responses.
| Video: (06:28) |
Introduction to Immunotherapy Research by Neil Riordan, PA-C, Ph.D.
|
Interest among the medical profession about high-dose intravenous Vitamin C is steadily growing. Reports come from around the world of doctors who have seen the benefits of high-dose intravenous Vitamin C. In our efforts, we hope to reduce the usual forty-year lag time between discovery and wide spread use of a new therapeutic modality.
Those that have and continue to benefit from holistic approaches including intravenous Vitamin C are true pioneers. Either because of or in spite of the treatment developed here and prescribed here and elsewhere, using methods that are not toxic to normal cells, they have eliminated any evidence of a variety of cancers, including adenocarcinoma of the breast, ductal carcinoma of the breast, lymphoma, bladder cancer and metastatic renal cancer.
Ongoing Clinical Applications of RECNAC Research:
1. A clinical trial for the treatment of metastatic renal cancer using vitamin C in combination with lipoic acid and the natural immune supplements Immunopower and BioPro is in progress at the Center.
2. The Center is in the process of patenting a natural plant extract, and soon hopes to make more information on this extract, and perhaps the extract itself, available to co-learners.
3. The immunotherapy and anti-angiogenesis technologies developed at RECNAC have been licensed to Aidan, Inc, which is making them available to cancer patients.
4. Through The Center’s “Beat the Odds” program, co-learners are able to have their antioxidant levels checked to be sure they are getting sufficient amounts of chemopreventative antioxidants.
Important Facts/Ideas Uncovered by RECNAC Research
1. Cancer patients are not only deficient in vitamin C, but they seem to have a large tissue demand for the vitamin.
2. The anti-tumor effect of vitamin C in a three-dimensional in vitro tumor model is increased substantially when applied in combination with lipoic acid or vitamin K3.
3. Phagocytes and lymphocytes obtained from people who supplement regularly with vitamin C have more activity in tests than those obtained from people who do not supplement.
4. The growth of dendritic cells, the cytotoxicity of T-lymphocytes, and the production of cytokines by stimulated monocytes, can be affected by variables such as cell density, incubation time, and vitamin C supplementation.
5. The application of low frequency magnetic fields can improve the anti-cancer effects of vitamin C and improve the proliferation of stimulated lymphocytes.
6. Blood contains red blood cell “inclusion bodies” that are made of cell membrane materials. These may be indicators of health problems.
7. Slight variations in temperature and the presence of electric or magnetic fields can affect cell growth.
8. The composition of fatty acids in cancer cells differs from that in normal cells, suggesting that cancer might be controlled by adjusting fatty acid balance.
The Impact of RECNAC on Future work at The Biocommunications Research Institute
1. The Biocommunications Research Institute, using techniques developed during the RECNAC project, is intensifying efforts to learn how nutrients and nutrient supplementation affect immune cell functioning.
2. The Biocommunications Research Institute will continue to be at the forefront of vitamin C related research. Building on RECNAC project results, the Institute will launch investigations of tissue vitamin C utilization and the effects of vitamin C depletion and supplementation on vitamin C stores and on health.
3. The Biocommunications Research Institute will expand studies concerning how subtle energies affect cells and people.
4. Development and analysis of phytochemical remedies will continue using the expertise gained by the Biocommunications Research Institute during its efforts in the RECNAC project.
References
1. Case Study: High-Dose Intravenous Vitamin C in the Treatment of a Patient with Adenocarcinoma of the Kidney, Riordan, H. D., Jackson, J. A., and Schultz, M., Journal of Orthomolecular Medicine, 5: 5-7, 1990.
2. Improved Microplate Fluorometer Counting of Viable Tumor and Normal Cells, Riordan, H. D., Riordan N. H., Meng, X., Zhong, J., Jackson, J. A., Anticancer Research, 14: 927-932, 1994.
3. High Dose Intravenous Vitamin C and Long Time Survival of a Patient with Cancer of the Head of the Pancreas, Jackson, J. A., Riordan, H. D., Hunninghake, R. E., and Riordan, N. H., Journal of Orthomolecular Medicine., 10: 87-88, 1995.
4. Intravenous Ascorbate as a Tumor Cytotoxic Chemotherapeutic Agent. Riordan, N. H., Riordan, H. D., Meng, X., Li, Y., and Jackson, J. A. , Medical Hypotheses, 44(3), 207-13. 1995.
5. High-dose Intravenous Vitamin C in the Treatment of a Patient with Renal Cell Carcinoma of the Kidney, Riordan, H. D., Jackson, J. A., Riordan, N. H., and Schultz, M., Journal of Orthomolecular Medicine, 13: 72-73, 1998.
6. Cytotoxicity of Ascorbate, Lipoic Acid, and Other Antioxidants in Hollow Fibre in Vitro Tumours, Casciari J, Riordan N, Schmidt T, Meng X, Jackson J, Riordan H, British Journal of Cancer, 2001, 84(11):1544-1550.
7. Effects of a High Molecular Mass Convolvulus Arvensis Extract on Tumor Growth and Angiogenesis, Meng X, Riordan N, Casciari J, Zhu Y, Zhong J, Gonzalez M, Miranda-Massari J, Riordan H, Puero Rico Health Sciences Journal, 2002, 21(4):323-328.
Patents
1. Riordan, N. H., Riordan, H. D., Therapeutic method for the treatment of cancer. U.S. Patent No. 5,639,787, 1997.
2. Casciari, J. J., Riordan, H. D., and Riordan, N. H., Treatment of cancer using lipoic acid in combination with ascorbic acid. Pending.
3. Meng, X., Riordan, H. D., Riordan, N. H., Casciari J. J., and Taylor, P. T., Immune stimulating bacterial cell wall extracts. (To be submitted in 2000).
4. Meng, X., Riordan, N. H., Riordan, H. D., High molecular weight extracts of convolvulus arvensis (field bindweed). Pending.
5. Mikirova, N., et al, Method for improving therapeutic effectiveness of Ascorbic Acid for cancer treatment by using electromagnetic field exposure. (To be submitted in 2000).
6. Riordan, N. H., et al., Pharmaceutical preparation of cytokine production from mononuclear cells.
Our Research has been made possible by generous contributions by many many individuals, corporations and foundations. Because we do not accept tax derived government monies, our research depends solely upon private funding. We are grateful for the support of our research by Bob and Marge Page, The Olive White Garvey Trust, members of the Garvey family, Frank Horton, Bob Marietta, Dave and Sue O’Malley, The Flossie West Trust and the more than 1,000 contributors who receive “Throwing a Rope”.
